A free webinar on June 30 will bring members of the myasthenia gravis (MG) community together to discuss the daily realities of life with the chronic condition, from managing unpredictable workplace symptoms to recognizing the early warning signs of a flare. The event, titled “Navigating MG Day,” will…
News
A simple model that uses five clinical factors could help doctors predict which people with ocular myasthenia gravis (OMG) are most likely to achieve minimal symptoms or better within one year, according to a study in China. “Based on prognostic predictions, early efforts can be made to develop therapeutic interventions…
Ublituximab-xiiy, an approved medication for certain types of multiple sclerosis (MS), was shown to safely and effectively reduce disease severity in people with myasthenia gravis (MG) who have self-reactive antibodies against the acetylcholine receptor (AChR) protein. That’s according to new data from an early-stage clinical trial that tested the…
The infusion therapy Imaavy (nipocalimab) is now approved in the U.K. for treating people ages 12 and older with generalized myasthenia gravis (MG). The new authorization by the Medicines and Healthcare Products Regulatory Agency (MHRA), the body that regulates the use of medications in Great Britain, allows the…
For most people with mild, stable myasthenia gravis (MG), taking a low dose of trazodone hydrochloride, an oral antidepressant also commonly used as a sleep aid, can help ease insomnia —difficulty falling asleep, staying asleep, or waking up too early — without worsening MG symptoms or causing breathing…
News
by Patricia Inacio, PhD
Seronegative MG more rare than previously thought: Danish study
People with myasthenia gravis (MG) who lack detectable MG-related antibodies, known as seronegative MG, may be rarer than previously suggested, according to a single-center study in Denmark. Researchers identified seronegative MG in only 4.3% of 350 cases — a percentage lower than the roughly 10% reported in earlier studies.
The Muscular Dystrophy Association (MDA) is hosting a series of four free, in-person educational events across the U.S. to support families affected by neuromuscular diseases, including myasthenia gravis (MG). Part of the 2026 MDA Engage Symposium series, these upcoming gatherings will connect attendees directly with medical experts, the…
Treatments that suppress or alter immune system activity may help some children and adolescents with juvenile myasthenia gravis (JMG), but more studies are needed to help define the potential benefits and determine best practices. That’s according to a meta-analysis of published studies reporting outcomes of JMG patients who were…
June is Myasthenia Gravis Awareness Month, and advocates around the world are planning a range of events to raise awareness of myasthenia gravis (MG). “MG community members, including patients, care partners, and healthcare providers, host advocacy activities in June each year to promote a broader global understanding of the…
Treatment with Vyvgart (efgartigimod) was associated with rapid and sustained symptom easing, lower corticosteroid use, and no unexpected safety concerns in a small real-world study of adults with generalized myasthenia gravis (gMG). The findings suggest the therapy may be a useful option in individualized treatment plans, although larger,…
Recent Posts
- Confronting and processing the complexity of a rare disease diagnosis
- Free webinar on June 30 explores life with MG beyond the clinic
- Being the partner of someone with MG requires support, too
- Medication fatigue is an unavoidable reality of life with chronic illness
- Model may predict treatment outcomes in ocular myasthenia gravis